Windlas Biotech Limited commissions its State-of-the-Art Injectable facility

Windlas Biotech Limited has announced the commissioning of its state-of-the-art injectable facility for manufacturing of Small Volume Parenteral products, built to meet international cGMP standards.

The Company has received manufacturing license from the Drug Controlling & Licensing Authority of Uttarakhand after joint inspection conducted by Central Drugs Standard Control Organisation and State Licensing Authority of Uttarakhand. The facility has initiated manufacturing of commercial batches and we expect to introduce several new products over the course of Financial Year 2025.

This milestone marks company's continued foray in development and manufacturing of complex dosage forms like Ampoules, Liquid Vials and Lyophilized Vials thereby extending its product portfolio to critical care and other specialized therapeutic segments. This Injectable plant shall cater to all three of our business verticals: CDMO, Trade Generics & Institutional, and Exports.

Commenting on this achievement, Mr. Hitesh Windlass, Managing Director, Windlas Biotech said, "The commissioning of our injectable facility is a landmark event for us, signifying our dedication to bringing advanced and life-saving treatments to the market. This facility not only enhances our manufacturing capabilities across a new dosage format, but also demonstrates our commitment to excellence and innovation in pharmaceutical manufacturing. We are poised to meet the evolving demands of our valued customers and solidify our position as one of the frontrunners in the industry. We remain dedicated to upholding the high standards of quality, compliance, and customer satisfaction as we continue to drive innovation and growth in the pharmaceutical landscape."

Shares of Windlas Biotech Ltd was last trading in BSE at Rs. 541.50 as compared to the previous close of Rs. 512.35. The total number of shares traded during the day was 11894 in over 996 trades.

The stock hit an intraday high of Rs. 548.45 and intraday low of 512.50. The net turnover during the day was Rs. 6367616.00.

Source : Equity Bulls

Keywords

WindlasBiotech InjectableFacility Commissioned StateoftheArt cGMP